Investment and Company Research
Opportunity Research
MICROCAP HOT TOPICS
 

August 30, 2013

Plandaí Biotechnology’s Phytofare™Citrus Products Aid Diabetics

Plandaí­ Biotechnology (OTCQB – PLPL - $0.67 – Spec Buy) is set to release the Phyto Nutricare line in the first quarter of 2014, leading with the Phytofare™ Catechin Complex products.  This launch will be shortly followed by the Phytofare™ Limonoid Glycoside Complex products later in the summer, which could be a boon to diabetics, the elderly, and others that suffer from capillary and circulatory problems.  The Limonoid Glycoside products are made lemons and utilize the entire fruit—pith, peel, pulp and juice, to extract all soluble phytonutrients, including vitamins A & C, bioflavonoids, and variety of minerals including potassium and pectin.  

In a 2010 study at Canadian-based KGK Synergize, it was deduced that daily supplements of citrus limonoids and bioflavonoids may reduce factors for diabetes such as glucose tolerance.  The findings were published in the Journal of Functional Foods.

http://www.nutraingredients-usa.com/Research/Citrus-extract-shows-benefits-for-diabetics-Study

The human trial portion of the tests involved 19 subjects with impaired fasting glucose.  The study found that the LDL cholesterol levels were lowered in 13 of the 19 test subjects, and more importantly, related to diabetes, a significant reduction in glucose intolerance was observed.

Diabetes has become a major health issue in the United States and other industrialized nations.  According to the American Diabetes Association, nearly 24 million people in the United States, or 8% of the population, have either Type I or Type II diabetes.   Additionally, according to the International Diabetes Federation (IDF), more than 370 million people have diabetes worldwide, with Type II accounting for 90-95% of all cases.  Additionally, the IDF estimates that by 2030 about 550 million people could have the disease.  Alternative and preventive measures like the supplements found in the Citrus Limonoid Glycoside Complex Phytofare™ products from Plandaí­ will be a key in stopping the proliferation of the diabetes epidemic.

Plandaí­ Biotechnology’s key catalyst in product success is its bioavailability, or the level of absorption into the blood stream from the extracts.  The Phytofare™ Limonoid Glycoside Complex product will offer substantially higher bioavailability compared to products currently on the market, which is a huge advantage for the Company.  The rollout and associated aggressive marketing should pave the way for the Company to profit from the superior products that target what is unfortunately a large and ever-growing diabetes prevention market throughout the globe.

For more information, refer to our previous PLPL Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com

Senior Analyst: Robert Goldman
Rob Goldman has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

Analyst Certification
I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

Disclaimer
This Opportunity Research Hot Topics article was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports. It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. While stocks in the Opportunity format may have a higher risk profile, they typically offer greater upside as well. Since May 2013, Goldman Small Cap Research has been compensated $500 per article by a third party and $4,000 for a research report service.  

Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.

This article is the opinion of Goldman Small Cap Research and was written based upon publicly available information.  The Company has not endorsed or compensated Goldman Small Cap Research for this article. All information contained in this report was provided by the Company or derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com